BIOMAT Database Logo BIOMAT Database Logo

[Adjuvant surgery for lung cancer]. 1989

T Shindo, and H Wada, and S Hitomi

Recently several trials of adjuvant surgery or so-called neo-adjuvant chemotherapy have been reported about lung cancer. The indication of this therapy contains not only small cell lung cancers but also non-small cell lung cancers in most recent report. However, the therapeutic outcome is not satisfactory especially in N2 cases, better local control and, even a few, long time survivors were reported with this therapy. In our own experience of 10 cases since 1981, same tendency was recognized. So several type of controlled studies are necessary for the evaluation of adjuvant surgery to lung cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D018288 Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) Carcinoma, Oat Cell,Oat Cell Carcinoma,Small Cell Carcinoma,Carcinomas, Oat Cell,Carcinomas, Small Cell,Oat Cell Carcinomas,Small Cell Carcinomas

Related Publications

T Shindo, and H Wada, and S Hitomi
[Evaluation of adjuvant therapy for lung cancer surgery].
March 1978, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
T Shindo, and H Wada, and S Hitomi
Cytoxan as an adjuvant to surgery for lung cancer.
January 1969, Journal of surgical oncology,
T Shindo, and H Wada, and S Hitomi
[Surgery of lung cancer and adjuvant therapy].
March 1978, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
T Shindo, and H Wada, and S Hitomi
Chemotherapy plus adjuvant surgery for local small cell lung cancer.
August 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
T Shindo, and H Wada, and S Hitomi
[Adjuvant chemotherapy for non-small cell lung cancer. WJSG: West Japan Study Group for Lung Cancer Surgery].
October 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
T Shindo, and H Wada, and S Hitomi
Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy.
September 1997, Oncology (Williston Park, N.Y.),
T Shindo, and H Wada, and S Hitomi
[Adjuvant immunotherapy for lung cancer].
May 2002, Nihon rinsho. Japanese journal of clinical medicine,
T Shindo, and H Wada, and S Hitomi
[Adjuvant chemotherapy for lung cancer].
September 1985, Nihon Geka Gakkai zasshi,
T Shindo, and H Wada, and S Hitomi
Adjuvant therapy for lung cancer.
December 2009, Minerva chirurgica,
T Shindo, and H Wada, and S Hitomi
Adjuvant chemotherapy for lung cancer.
April 2004, The New England journal of medicine,
Copied contents to your clipboard!